Literature DB >> 20498632

Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas.

J Braun1, C Hoang-Vu, H Dralle, S Hüttelmaier.   

Abstract

Anaplastic thyroid carcinomas (ATCs) arise from epithelial thyroid cells by mesenchymal de-/transdifferentiation and rapidly invade the adjacent tissue. Specific microRNA signatures were suggested to distinguish ATCs from normal thyroid tissue and other thyroid carcinomas of follicular origin. Whether distinct microRNA patterns correlate with de-/transdifferentiation and invasion of ATCs remained elusive. We identified two significantly decreased microRNA families that unambiguously distinguish ATCs from papillary and follicular thyroid carcinomas: miR-200 and miR-30. Expression of these microRNAs in mesenchymal ATC-derived cells reduced their invasive potential and induced mesenchymal-epithelial transition (MET) by regulating the expression of MET marker proteins. Supporting the role of transforming growth factor (TGF)beta signaling in modulating MET/epithelial-mesenchymal transition (EMT), expression of SMAD2 and TGFBR1, upregulated in most primary ATCs, was controlled by members of the miR-30 and/or miR-200 families in ATC-derived cells. Inhibition of TGFbeta receptor 1 (TGFBR1) in these cells induced MET and reduction of prometastatic miR-21, but caused an increase of the miR-200 family. These findings identify altered microRNA signatures as potent markers for ATCs that promote de-/transdifferentiation (EMT) and invasion of these neoplasias. Hence, TGFBR1 inhibition could have a significant potential for the treatment of ATCs and possibly other invasive tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498632     DOI: 10.1038/onc.2010.169

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  125 in total

1.  MicroRNA-200 is induced by thioredoxin-interacting protein and regulates Zeb1 protein signaling and beta cell apoptosis.

Authors:  Stephen R Filios; Guanlan Xu; Junqin Chen; Kyunghee Hong; Gu Jing; Anath Shalev
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

Review 2.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

Review 3.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 4.  Evolutionary functional analysis and molecular regulation of the ZEB transcription factors.

Authors:  Alexander Gheldof; Paco Hulpiau; Frans van Roy; Bram De Craene; Geert Berx
Journal:  Cell Mol Life Sci       Date:  2012-02-21       Impact factor: 9.261

5.  Low SLC29A1 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Ping-Ting Gao; Jian-Wen Cheng; Zi-Jun Gong; Bo Hu; Yun-Fan Sun; Ya Cao; Shuang-Jian Qiu; Jian Zhou; Jia Fan; Xin-Rong Yang
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

6.  Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells.

Authors:  Suzan Schwertheim; Frederik Wein; Klaus Lennartz; Karl Worm; Kurt Werner Schmid; Sien-Yi Sheu-Grabellus
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-06       Impact factor: 4.553

7.  MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19.

Authors:  Yanping Gong; Wenshuang Wu; Xiuhe Zou; Feng Liu; Tao Wei; Jingqiang Zhu
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

Review 8.  Epithelial-to-mesenchymal transition in tumor progression.

Authors:  Elena Prieto-García; C Vanesa Díaz-García; Inmaculada García-Ruiz; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2017-05-30       Impact factor: 3.064

9.  MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.

Authors:  Ranran Zhang; Heather Hardin; Wei Huang; Jidong Chen; Sofia Asioli; Alberto Righi; Francesca Maletta; Anna Sapino; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

10.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.